Top

Published in:

Open Access 01-12-2009 | Research article

Arrested neural and advanced mesenchymal differentiation of glioblastoma cells-comparative study with neural progenitors

Authors: Piotr Rieske, Ewa Golanska, Magdalena Zakrzewska, Sylwester Piaskowski, Krystyna Hulas-Bigoszewska, Magdalena Wolańczyk, Malgorzata Szybka, Monika Witusik-Perkowska, Dariusz J Jaskolski, Krzysztof Zakrzewski, Wojciech Biernat, Barbara Krynska, Pawel P Liberski

Published in: BMC Cancer | Issue 1/2009

Abstract

Background

Although features of variable differentiation in glioblastoma cell cultures have been reported, a comparative analysis of differentiation properties of normal neural GFAP positive progenitors, and those shown by glioblastoma cells, has not been performed.

Methods

Following methods were used to compare glioblastoma cells and GFAP+NNP (NHA): exposure to neural differentiation medium, exposure to adipogenic and osteogenic medium, western blot analysis, immunocytochemistry, single cell assay, BrdU incorporation assay. To characterize glioblastoma cells EGFR amplification analysis, LOH/MSI analysis, and P53 nucleotide sequence analysis were performed.

Results

In vitro differentiation of cancer cells derived from eight glioblastomas was compared with GFAP-positive normal neural progenitors (GFAP+NNP). Prior to exposure to differentiation medium, both types of cells showed similar multilineage phenotype (CD44+/MAP2+/GFAP+/Vimentin+/Beta III-tubulin+/Fibronectin+) and were positive for SOX-2 and Nestin. In contrast to GFAP+NNP, an efficient differentiation arrest was observed in all cell lines isolated from glioblastomas. Nevertheless, a subpopulation of cells isolated from four glioblastomas differentiated after serum-starvation with varying efficiency into derivatives indistinguishable from the neural derivatives of GFAP+NNP. Moreover, the cells derived from a majority of glioblastomas (7 out of 8), as well as GFAP+NNP, showed features of mesenchymal differentiation when exposed to medium with serum.

Conclusion

Our results showed that stable co-expression of multilineage markers by glioblastoma cells resulted from differentiation arrest. According to our data up to 95% of glioblastoma cells can present in vitro multilineage phenotype. The mesenchymal differentiation of glioblastoma cells is advanced and similar to mesenchymal differentiation of normal neural progenitors GFAP+NNP.

Available only for authorised users

Günther HS, Schmidt NO, Phillips HS, Kemming D, Kharbanda S, Soriano R, Modrusan Z, Meissner H, Westphal M, Lamszus K: Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene. 2008, 27: 2897-909. 10.1038/sj.onc.1210949.CrossRefPubMed

Ignatova TN, Kukekov VG, Laywell ED, Suslov ON, Vrionis FD, Steindler DA: Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia. 2002, 39: 193-206. 10.1002/glia.10094.CrossRefPubMed

Tso CL, Shintaku P, Chen J, Liu Q, Liu J, Chen Z, Yoshimoto K, Mischel PS, Cloughesy TF, Liau LM, Nelson SF: Primary glioblastomas express mesenchymal stem-like properties. Mol Cancer Res. 2006, 9: 607-19. 10.1158/1541-7786.MCR-06-0005.CrossRef

Ricci-Vitiani L, Pallini R, Larocca LM, Lombardi DG, Signore M, Pierconti F, Petrucci G, Montano N, Maira G, De Maria R: Mesenchymal differentiation of glioblastoma stem cells. Cell Death Differ. 2008, 15: 1491-8. 10.1038/cdd.2008.72.CrossRefPubMed

Rieske P, Azizi SA, Augelli B, Gaughan J, Krynska B: A population of human brain parenchymal cells express markers of glial, neuronal and early neural cells and differentiate into cells of neuronal and glial lineages. Eur J Neurosci. 2007, 25 (1): 31-37. 10.1111/j.1460-9568.2006.05254.x.CrossRefPubMed

Witusik M, Gresner SM, Hulas-Bigoszewska K, Krynska B, Azizi SA, Liberski PP, Brown P, Rieske P: Neuronal and astrocytic cells, obtained after differentiation of human neural GFAP-positive progenitors, present heterogeneous expression of PrPc. Brain Res. 2007, 1186: 65-73. 10.1016/j.brainres.2007.10.039.CrossRefPubMed

Witusik M, Piaskowski S, Hulas-Bigoszewska K, Zakrzewska M, Gresner SM, Azizi AS, Krynska B, Liberski PP, Rieske P: Successful elimination of non-neural cells and unachievable elimination of glial cells by means of commonly used cell culture manipulations during differentiation of GFAP and SOX2-positive neural progenitors (NHA) to neuronal cells. BMC Biotechnol. 2008, 8: 56-10.1186/1472-6750-8-56.CrossRefPubMedPubMedCentral

Rieske P, Augelli BJ, Stawski R, Gaughan J, Azizi SA, Krynska B: A Population of Human Brain Cells Expressing Phenotypic Markers of More Than One Lineage Can Be Induced In Vitro to Differentiate into Mesenchymal Cells. Exp Cell Res. 2009, 315: 462-73. 10.1016/j.yexcr.2008.11.004.CrossRefPubMed

Rieske P, Kordek R, Bartkowiak J, Debiec-Rychter M, Biernat W, Liberski PP: comparative study of epidermal growth factor receptor (EGFR) and MDM2 gene amplification and protein immunoreactivity in human glioblastomas. Pol J Pathol. 1998, 49: 145-9.PubMed

10.

Szybka M, Bartkowiak J, Zakrzewski K, Polis L, Liberski P, Kordek R: Microsatellite instability and expression of DNA mismatch repair genes in malignant astrocytic tumors from adult and pediatric patients. Clin Neuropathol. 2003, 22: 180-6.PubMed

11.

Ohgaki H, Eibl RH, Schwab M, Reichel MB, Mariani L, Gehring M, Petersen I, Höll T, Wiestler OD, Kleihues P: Mutations of the p53 tumor suppressor gene in neoplasms of the human nervous system. Mol Carcinog. 1993, 8: 74-80. 10.1002/mc.2940080203.CrossRefPubMed

12.

Biernat W, Tohma Y, Yonekawa Y, Kleihues P, Ohgaki H: Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas. Acta Neuropathol. 1997, 94: 303-309. 10.1007/s004010050711.CrossRefPubMed

13.

von Deimling A, von Ammon K, Schoenfeld D, Wiestler OD, Seizinger BR, Louis DN: Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol. 1993, 3: 19-26. 10.1111/j.1750-3639.1993.tb00721.x.CrossRefPubMed

14.

Zipori D: The nature of stem cells: state rather than entity. Nat Rev Genet. 2004, 5: 873-878. 10.1038/nrg1475.CrossRefPubMed

15.

Egusa H, Schweizer FE, Wang CC, Matsuka Y, Nishimura I: Neuronal differentiation of bone marrow-derived stromal stem cells involves suppression of discordant phenotypes through gene silencing. J Biol Chem. 2005, 280: 23691-23697. 10.1074/jbc.M413796200.CrossRefPubMed

16.

Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, Aigner L, Brawanski A, Bogdahn U, Beier CP: CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 2007, 67: 4010-4015. 10.1158/0008-5472.CAN-06-4180.CrossRefPubMed

17.

Ellis P, Fagan BM, Magness ST, Hutton S, Taranova O, Hayashi S, McMahon A, Rao M, Pevny L: SOX2, a persistent marker for multipotential neural stem cells derived from embryonic stem cells, the embryo or the adult. Dev Neurosci. 2004, 26: 148-165. 10.1159/000082134.CrossRefPubMed

18.

Temple S: The development of neural stem cells. Nature. 2001, 414: 112-117. 10.1038/35102174.CrossRefPubMed

19.

Biernat W, Aguzzi A, Sure U, Grant JW, Kleihues P, Hegi ME: Identical mutations of the p53 tumor suppressor gene in the gliomatous and the sarcomatous components of gliosarcomas suggest a common origin from glial cells. J Neuropathol Exp Neurol. 1995, 54: 651-656. 10.1097/00005072-199509000-00006.CrossRefPubMed

20.

Boerman RH, Anderl K, Herath J, Borell T, Johnson N, Schaeffer-Klein J, Kirchhof A, Raap AK, Scheithauer BW, Jenkins RB: The glial and mesenchymal elements of gliosarcomas share similar genetic alterations. J Neuropathol Exp Neurol. 1996, 55: 973-81. 10.1097/00005072-199609000-00004.CrossRefPubMed

21.

McBratney-Owen B, Iseki S, Bamforth SD, Olsen BR, Morriss-Kay GM: Development and tissue origins of the mammalian cranial base. Dev Biol. 2008, 322: 121-32. 10.1016/j.ydbio.2008.07.016.CrossRefPubMedPubMedCentral

22.

Sailer MH, Hazel TG, Panchision DM, Hoeppner DJ, Schwab ME, McKay RD: BMP2 and FGF2 cooperate to induce neural-crest-like fates from fetal and adult CNS stem cells. J Cell Sci. 2005, 118: 5849-60. 10.1242/jcs.02708.CrossRefPubMed

23.

Laywell ED, Kearns SM, Zheng T, Chen KA, Deng J, Chen HX, Roper SN, Steindler DA: Neuron-to-astrocyte transition: phenotypic fluidity and the formation of hybrid asterons in differentiating neurospheres. J Comp Neurol. 2005, 493: 321-33. 10.1002/cne.20722.CrossRefPubMedPubMedCentral

24.

Hu M, Krause D, Greaves M, Sharkis S, Dexter M, Heyworth C, Enver T: Multilineage gene expression precedes commitment in the hemopoietic system. Genes Dev. 1997, 11: 774-85. 10.1101/gad.11.6.774.CrossRefPubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/9/54/prepub

Title: Arrested neural and advanced mesenchymal differentiation of glioblastoma cells-comparative study with neural progenitors
Authors: Piotr Rieske
Ewa Golanska
Magdalena Zakrzewska
Sylwester Piaskowski
Krystyna Hulas-Bigoszewska
Magdalena Wolańczyk
Malgorzata Szybka
Monika Witusik-Perkowska
Dariusz J Jaskolski
Krzysztof Zakrzewski
Wojciech Biernat
Barbara Krynska
Pawel P Liberski
Publication date: 01-12-2009
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2009
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/1471-2407-9-54

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2009

Characterization of STAT3 activation and expression in canine and human osteosarcoma

Molecular fingerprinting of radiation resistant tumors: Can we apprehend and rehabilitate the suspects?

RNOP-09: Pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma - a phase II study

Health – related quality of life of Kuwaiti women with breast cancer: a comparative study using the EORTC Quality of Life Questionnaire

Transcribed-ultra conserved region expression is associated with outcome in high-risk neuroblastoma

Signalling with retinoids in the human lung: validation of new tools for the expression study of retinoid receptors

Keynote webinar | Spotlight on antibody–drug conjugates in cancer